Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
9 U, {& B' ]4 T' x, x* INOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 , E0 i9 R3 i j
+ Author Affiliations/ c. y. H+ j, y- ?
# X: L; G! O. S- Q. Q0 q: f! X6 R
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan 7 ~1 }+ X D, v6 R E3 I
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
( [7 ]7 ^- Y, e1 M7 ^# n0 e9 [) o3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan , a: e$ G6 i: l0 T/ u/ t& F2 r
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
/ ]1 f" W) X j e! |5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan : p: I! r- O/ e
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 8 G( U* Q- M" B- w: a
7Kinki University School of Medicine, Osaka 589-8511, Japan
M% t; u& V1 e8 W* T; Q' e c3 n8Izumi Municipal Hospital, Osaka 594-0071, Japan
( r E1 U9 s- Z' V) ^9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 8 J* ]4 s& ?' a5 E9 G0 w% ^
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
) A) K1 Y- X2 u4 R+ R, kAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
2 S+ i# P7 u4 `2 Z/ T* n5 n6 J& E4 H! t! c! f$ Q
|